News | November 05, 2021
UK authorises first Covid-19 pill
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Subscribe To Our Newsletter & Stay Updated
